Online inquiry

IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8558MR)

This product GTTS-WQ8558MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD47 gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) Cancers(CRC), Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001777.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 961
UniProt ID Q08722
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8558MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9186MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMGN853
GTTS-WQ1794MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ADCT-402
GTTS-WQ13222MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-05082566
GTTS-WQ3792MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ14135MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA aPCSK927
GTTS-WQ5535MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDP7657
GTTS-WQ6081MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CNTO 888
GTTS-WQ9680MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JNJ-64052781
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW